GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00027682 | Cervix | N_HPV | immune response-regulating cell surface receptor signaling pathway | 22/534 | 315/18723 | 1.11e-04 | 2.18e-03 | 22 |
GO:0002705 | Cervix | N_HPV | positive regulation of leukocyte mediated immunity | 13/534 | 134/18723 | 1.21e-04 | 2.33e-03 | 13 |
GO:00022632 | Cervix | N_HPV | cell activation involved in immune response | 20/534 | 279/18723 | 1.59e-04 | 2.82e-03 | 20 |
GO:007066121 | Cervix | N_HPV | leukocyte proliferation | 21/534 | 318/18723 | 3.38e-04 | 5.01e-03 | 21 |
GO:00023661 | Cervix | N_HPV | leukocyte activation involved in immune response | 19/534 | 275/18723 | 3.66e-04 | 5.35e-03 | 19 |
GO:00026992 | Cervix | N_HPV | positive regulation of immune effector process | 17/534 | 235/18723 | 4.36e-04 | 6.01e-03 | 17 |
GO:002260424 | Cervix | N_HPV | regulation of cell morphogenesis | 20/534 | 309/18723 | 5.98e-04 | 7.85e-03 | 20 |
GO:00603482 | Cervix | N_HPV | bone development | 15/534 | 205/18723 | 8.27e-04 | 1.02e-02 | 15 |
GO:0090136 | Cervix | N_HPV | epithelial cell-cell adhesion | 4/534 | 17/18723 | 1.16e-03 | 1.31e-02 | 4 |
GO:00302172 | Cervix | N_HPV | T cell differentiation | 17/534 | 257/18723 | 1.18e-03 | 1.33e-02 | 17 |
GO:190313121 | Cervix | N_HPV | mononuclear cell differentiation | 24/534 | 426/18723 | 1.27e-03 | 1.40e-02 | 24 |
GO:004586023 | Cervix | N_HPV | positive regulation of protein kinase activity | 22/534 | 386/18723 | 1.73e-03 | 1.75e-02 | 22 |
GO:003367422 | Cervix | N_HPV | positive regulation of kinase activity | 25/534 | 467/18723 | 2.05e-03 | 1.98e-02 | 25 |
GO:00085843 | Cervix | N_HPV | male gonad development | 11/534 | 141/18723 | 2.40e-03 | 2.18e-02 | 11 |
GO:004886313 | Cervix | N_HPV | stem cell differentiation | 14/534 | 206/18723 | 2.43e-03 | 2.20e-02 | 14 |
GO:00465463 | Cervix | N_HPV | development of primary male sexual characteristics | 11/534 | 142/18723 | 2.54e-03 | 2.28e-02 | 11 |
GO:004860822 | Cervix | N_HPV | reproductive structure development | 23/534 | 424/18723 | 2.58e-03 | 2.31e-02 | 23 |
GO:006145823 | Cervix | N_HPV | reproductive system development | 23/534 | 427/18723 | 2.81e-03 | 2.45e-02 | 23 |
GO:004668614 | Cervix | N_HPV | response to cadmium ion | 7/534 | 68/18723 | 3.18e-03 | 2.64e-02 | 7 |
GO:000721911 | Cervix | N_HPV | Notch signaling pathway | 12/534 | 172/18723 | 3.92e-03 | 3.08e-02 | 12 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05224 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa052241 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa04640 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
hsa046401 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0401023 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
hsa0415123 | Oral cavity | EOLP | PI3K-Akt signaling pathway | 73/1218 | 354/8465 | 7.03e-04 | 2.69e-03 | 1.59e-03 | 73 |
hsa0522121 | Oral cavity | EOLP | Acute myeloid leukemia | 19/1218 | 67/8465 | 2.20e-03 | 7.32e-03 | 4.32e-03 | 19 |
hsa040722 | Oral cavity | EOLP | Phospholipase D signaling pathway | 31/1218 | 148/8465 | 1.82e-02 | 4.67e-02 | 2.76e-02 | 31 |
hsa0523041 | Oral cavity | EOLP | Central carbon metabolism in cancer | 17/1218 | 70/8465 | 1.87e-02 | 4.75e-02 | 2.80e-02 | 17 |
hsa0401033 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KIT | SNV | Missense_Mutation | | c.656C>T | p.Ala219Val | p.A219V | P10721 | protein_coding | tolerated(0.25) | benign(0.019) | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
KIT | SNV | Missense_Mutation | | c.117N>G | p.Ile39Met | p.I39M | P10721 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
KIT | SNV | Missense_Mutation | | c.1295G>A | p.Gly432Glu | p.G432E | P10721 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
KIT | SNV | Missense_Mutation | rs753318751 | c.771G>T | p.Glu257Asp | p.E257D | P10721 | protein_coding | tolerated(0.62) | benign(0.011) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | rs386833402 | c.839N>T | p.Ala280Val | p.A280V | P10721 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | rs143772138 | c.2057N>A | p.Arg686His | p.R686H | P10721 | protein_coding | deleterious(0.01) | benign(0.096) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | novel | c.1391N>T | p.Ser464Leu | p.S464L | P10721 | protein_coding | tolerated(0.35) | benign(0.172) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | rs781633384 | c.106C>A | p.Pro36Thr | p.P36T | P10721 | protein_coding | tolerated(0.39) | benign(0.112) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
KIT | insertion | Nonsense_Mutation | novel | c.2253_2254insCAAGGAGACCTCAGTAAATATTATTGATGG | p.Asp751_Val752insGlnGlyAspLeuSerLysTyrTyrTerTrp | p.D751_V752insQGDLSKYY*W | P10721 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIT | SNV | Missense_Mutation | novel | c.2401A>G | p.Thr801Ala | p.T801A | P10721 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | | Pazopanib HCl | | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178102337 | SORAFENIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | | G007-LK | | 28611108 |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | | Sorafenib | SORAFENIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 4'-N-BENZOYLSTAUROSPORINE | | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL124660 | TANDUTINIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178102585 | DOVITINIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178102286 | QUIZARTINIB | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 328083485 | OSI-930 | |
3815 | KIT | CLINICALLY ACTIONABLE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TYROSINE KINASE, DRUG RESISTANCE, EXTERNAL SIDE OF PLASMA MEMBRANE | | OSI-930 | OSI-930 | |